WASHINGTON—Pharmaceutical giant Pfizer Inc. said Wednesday that it plans to apply for emergency use authorization in the United States for a potential COVID-19 vaccine “within days”, as it has shown the vaccine to be effective in a clinical study.
The two-dose vaccine, jointly developed with German firm BioNTech SE, met “all of the study’s primary efficacy endpoints,” the companies said in their press release, noting that an analysis indicated the vaccine was 95 percent effective in preventing the disease caused by the novel coronavirus.
Read more.
You may also like these stories:
US Biotech Firm Moderna Says Vaccine 94.5% Effective for COVID-19
Trump Says Biden ‘Won’ Because of Rigged US Election
US-North Korea Nuclear Talks May Be Back to Square One Under Biden
